UBS Group Begins Coverage on Revvity (NYSE:RVTY)

Research analysts at UBS Group initiated coverage on shares of Revvity (NYSE:RVTY) in a research report issued on Wednesday, MarketBeat reports. The firm set a “neutral” rating and a $140.00 price target on the stock. UBS Group’s price objective points to a potential upside of 14.85% from the company’s current price.

Other analysts have also issued reports about the stock. Zacks Research raised shares of Revvity from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Wolfe Research assumed coverage on shares of Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Wall Street Zen lowered shares of Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. TD Cowen reissued a “buy” rating on shares of Revvity in a research report on Wednesday, July 15th. Finally, Royal Bank Of Canada started coverage on shares of Revvity in a research note on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 target price on the stock. Four research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $116.57.

Revvity Trading Down 4.1%

NYSE RVTY traded down $5.18 during trading on Wednesday, hitting $121.90. The stock had a trading volume of 82,585 shares, compared to its average volume of 1,401,964. Revvity has a one year low of $81.22 and a one year high of $133.00. The stock has a 50 day simple moving average of $117.12 and a 200 day simple moving average of $102.75. The stock has a market capitalization of $13.60 billion, a price-to-earnings ratio of 58.37, a P/E/G ratio of 2.37 and a beta of 1.09. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.20. The firm had revenue of $729.69 million for the quarter, compared to the consensus estimate of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The company’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts predict that Revvity will post 5.37 earnings per share for the current year.

Institutional Trading of Revvity

A number of hedge funds have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC bought a new position in Revvity in the second quarter worth about $171,000. Nykredit A S bought a new stake in shares of Revvity in the 2nd quarter valued at about $358,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Revvity in the 2nd quarter worth approximately $823,000. California State Teachers Retirement System grew its position in shares of Revvity by 10,607.8% in the 2nd quarter. California State Teachers Retirement System now owns 14,328,063 shares of the company’s stock worth $1,594,140,000 after buying an additional 14,194,254 shares during the last quarter. Finally, Angeles Wealth Management LLC raised its stake in shares of Revvity by 2.0% during the 2nd quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company’s stock worth $646,000 after acquiring an additional 112 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.